{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:06:33Z","timestamp":1763017593984},"reference-count":20,"publisher":"Japanese Society of Internal Medicine","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2015]]},"DOI":"10.2169\/internalmedicine.54.5405","type":"journal-article","created":{"date-parts":[[2015,10,14]],"date-time":"2015-10-14T22:23:26Z","timestamp":1444861406000},"page":"2603-2607","source":"Crossref","is-referenced-by-count":7,"title":["Effect of Adalimumab on an Enterocutaneous Fistula in Patients with Crohn's Disease: A Case Series"],"prefix":"10.2169","volume":"54","author":[{"given":"Kaori","family":"Fujiwara","sequence":"first","affiliation":[{"name":"Second Department of Internal Medicine, Osaka Medical College, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Inoue","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Osaka Medical College, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Yorifuji","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Osaka Medical College, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Munetaka","family":"Iguchi","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Osaka Medical College, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taisuke","family":"Sakanaka","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Osaka Medical College, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Narabayashi","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Osaka Medical College, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Kakimoto","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Osaka Medical College, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadaharu","family":"Nouda","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Osaka Medical College, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Okada","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Osaka Medical College, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Abe","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Osaka Medical College, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihisa","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Osaka Medical College, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhide","family":"Higuchi","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Osaka Medical College, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Van Deventer SJ. Tumour necrosis factor and Crohn's disease. Gut 40: 443-448, 1997.","DOI":"10.1136\/gut.40.4.443"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology 122: 1592-1608, 2002.","DOI":"10.1053\/gast.2002.33426"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Shah B, Mayer L. Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease. Expert Rev Clin Immunol 6: 607-620, 2010.","DOI":"10.1586\/eci.10.45"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 8: 244-250, 2002.","DOI":"10.1097\/00054725-200207000-00002"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Judge TA, Lichtenstein GR. Treatment of fistulizing Crohn's disease. Gastroenterol Clin North Am 33: 421-454, 2004.","DOI":"10.1016\/j.gtc.2004.03.002"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Nielsen OH, Rogler G, Hahnloser D, Thomsen OØ. Diagnosis and management of fistulizing Crohn's disease. Nat Clin Pract Gastroenterol Hepatol 6: 92-106, 2009.","DOI":"10.1038\/ncpgasthep1340"},{"key":"7","unstructured":"7. Vermeire S, van Assche G, Rutgeerts P. Review article: altering the natural history of Crohn's disease: evidence for and against current therapies. Aliment Pharmacol Ther 25: 3-12, 2007."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340: 1398-1405, 1999.","DOI":"10.1056\/NEJM199905063401804"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Amiot A, Setakhr V, Seksik P, et al. Long-term outcome of enterocutaneous fistula in patients with Crohn's disease treated with anti-TNF therapy: a cohort study from the GETAID. Am J Gastroenterol 109: 1443-1449, 2014.","DOI":"10.1038\/ajg.2014.183"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Kouklakis G, Efremidou EI, Zezos P, et al. Adalimumab: an effective and promising treatment for patients with fistulizing Crohn's disease: a case series. J Med Case Rep 5: 109, 2011.","DOI":"10.1186\/1752-1947-5-109"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 123: 132-142, 1995.","DOI":"10.7326\/0003-4819-123-2-199507150-00009"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 302: 981-987, 1980.","DOI":"10.1056\/NEJM198005013021801"},{"key":"13","unstructured":"13. Hanauer SB, Smith MB. Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporin A. Am J Gastroenterol 88: 646-649, 1993."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350: 876-885, 2004.","DOI":"10.1056\/NEJMoa030815"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132: 52-65, 2007.","DOI":"10.1053\/j.gastro.2006.11.041"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Colombel JF, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut 58: 940-948, 2009.","DOI":"10.1136\/gut.2008.159251"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Ishida K, Inoue T, Fujiwara K, et al. Clinical effects of adalimumab treatment with concomitant azathioprine in Japanese Crohn's disease patients. World J Gastroenterol 19: 2676-2682, 2013.","DOI":"10.3748\/wjg.v19.i17.2676"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kopylov U, Al-Taweel T, Yaghoobi M, et al. Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: a systematic review and meta-analysis. J Crohns Colitis 8: 1632-1641, 2014.","DOI":"10.1016\/j.crohns.2014.07.003"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Yuasa S, Yamaguchi H, Nakanishi Y, et al. Treatment responses and their predictors in patients with rheumatoid arthritis treated with biological agents. J Med Invest 60: 77-90, 2013.","DOI":"10.2152\/jmi.60.77"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Arends S, Brouwer E, van der Veer E, et al. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther 13: R94, 2011.","DOI":"10.1186\/ar3369"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/54\/20\/54_54.5405\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T15:21:57Z","timestamp":1567264917000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/54\/20\/54_54.5405\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":20,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.54.5405","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}